Open AccessPopulation Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis
Author(s) -
Bryan McGee,
Reynaldo Dietze,
David Jamil Hadad,
Lucilia Pereira Molino,
Ethel Leonor Nóia Maciel,
W. Henry Boom,
Moisés Palaci,
John L. Johnson,
Charles A. Peloquin
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01378-08
Subject(s) - linezolid , pharmacokinetics , tuberculosis , medicine , population pharmacokinetics , pulmonary tuberculosis , population , antibacterial agent , intensive care medicine , antibiotics , pharmacology , microbiology and biotechnology , biology , environmental health , pathology , staphylococcus aureus , bacteria , genetics , vancomycin
Nineteen adults with pulmonary tuberculosis received linezolid (600 mg) once or twice daily in an early bactericidal activity trial. A one-compartment population model produced median values for the absorption rate constant, volume of distribution, and elimination rate constant of 1.5 h(-1), 29.6 liters, and 0.25 h(-1) (once daily) and 2.7 h(-1), 32.1 liters, and 0.15 h(-1) (twice daily). Linezolid administered twice daily produced higher values for free drug area under the concentration-time curve (AUC)/MIC and time above MIC. Both regimens achieved free AUC/MIC ratios > 100. Median times above the MIC for free drug were 100% (twice daily) and 63% (once daily).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom